





# Therapeutic Applications of Nitric Oxide in Cancer and Inflammatoryrelated Disorders

Accademia dei Fisiocritici (Siena), October 4<sup>th</sup>-5<sup>th</sup>, 2018

#### Day 1: Thursday, October 4th

10-10:30am Greetings from the Authorities

Francesco Frati, Rector of University of Siena Cosima Baldari, Director of Dept. Life Sciences

Alessandro Mugelli, SIF President

Carlo Riccardi, Salvatore Cuzzocrea, Gruppo di lavoro SIF Infiammazione

Opening address: Lucia Morbidelli

General introduction of the meeting: Benjamin Bonavida

## I. Nitric Oxide and Cancer

#### Session 1

## Nitric Oxide roles in tumor progression and regression

Chairs: Jordi Muntane, Marina Ziche

### 10:30-11:00am

John Wallace - University of Calgary

Plenary lecture: Potential for Chemoprevention with Nitric Oxide and Hydrogen Sulfide-Releasing Drugs

11:00-11:15am

Salvatore Rizza - Danish Cancer Society Research Center

The Roles of the Denitrosylase GSNOR in Tumor Progression

11:15-11:30am

Khosrow Kashfi - University of New York School of Medicine

Nitric oxide and cancer: To inhibit or to induce iNOS – That is the Question?

11:30-11:45am

Karim Zuhra - Sapienza University of Rome

H<sub>2</sub>S Metabolism in Colon Cancer Cells Exposed to Hypoxia

11:45-12:15pm Coffee Break

#### Session 2

#### Nitric Oxide and Cancer Cell Death

Chairs: Sharon Glynn, Cristiana Perrotta

12:15-12:30pm

Moran Benhar - Technion-Israel Institute of Technology

**Characterization of Nitroso-Redox Stress-Induced Cancer Cell Death** 

12:30-12:45pm

Arnold Stern - New York University School of Medicine

Pro-Apoptotic Effects of S-Nitrosothiols O-Chloro and M-Chloro S-Nitroso-Aryl-Amides in Human Breast Cancer Cell Lines

12:45-1:00pm

Valerio Ciccone – University of Siena

**Antitumor Effect of a Metal Nonoate Through Angiogenesis Impairment** 

1:00-1:15pm

Lorenzo Cinci – University of Florence

New NO-Releasing Doxorubicins as Targeted Therapy Against Chemoresistance in Castration-Resistant

**Prostate Cancer: In Vitro and in Vivo Evaluations** 

<u>1:15 -1:45pm</u> General discussion (Chairs: Jordi Muntane, Marina Ziche, Sharon Glynn, Cristiana Perrotta)

1:30-2:30pm Lunch

#### Session 3

#### Nitric Oxide and therapy (I)

Chairs: Carlo Riccardi, Stefan Chlopicki

2:30-2:45pm

Greta Varchi – University of Bologna

Light Guided Production of Nitric Oxide and Singlet Oxygen for the Multi-modal treatment of cancer <u>2:45-3:00pm</u>

Claudiu T Supuran – University of Florence

Carbonic Anhydrase Inhibitor - NO Donor Hybrids and Their Pharmacologic Applications

3:00-3:15pm

Massimo Venturelli - University of Verona

The Role of Nitric Oxide on Vascular Dysfunction During Aging and Alzheimer's Disease

<u>3:15-3:45pm</u> *Coffee break* 

Session 4

Nitric Oxide and Therapy (II)

Chairs: Valentina Rapozzi, Andreas Papapetropolous

3:45-4:00pm

Stavroula Baritaki – University of Crete

Nitric Oxide (NO): A Multifaceted Target for Reversal of Cancer Cell Pleiotropic Properties by NO-modulating Therapies

4:00-4:15pm

Cristiana Perrotta - Università degli Studi di Milano

Nitric Oxide in Cancer Resistance to Cisplatin: Tumor Associated Macrophages as Key Players

4:15-4:30pm

Joanna Kopecka - University of Torino

Nitric Oxide Re-Instates Doxorubicin Cytotoxic and Pro-Immunogenic Effects in Refractory Breast Cancer

4:30-4:45pm

Alma Martelli - University of Pisa

Anti-Cancer Activities of Erucin a H<sub>2</sub>S-donor Isothiocyanate from Eruca Sativa Mill.: Is H<sub>2</sub>S the Real Player?

4:45-5:00pm

Valentina Citi - University of Pisa

Anticancer Effect of a Novel H2S-Hybrid Molecule on Human Breast Adenocarcinoma (MFC-7) and Human Breast Epithelial (MCF-10A) Cell Lines

<u>5:00-5:30pm</u> General discussion (Chairs: Carlo Riccardi, Stefan Chlopicki, Valentina Rapozzi, Andreas Papapetropolous)

8:00pm Dinner in Contrada

Day 2: Friday, October 5<sup>th</sup>

# II. Nitric Oxide and Inflammatory Related Disorders

Session 5

Nitric oxide and cardiovascular diseases

Chairs: Maria Foti, Giuseppe Cirino

9:15-9:30am

Perwez Hussain - National Cancer Institute, Bethesda, Maryland

Nitric oxide (NO•)/kynurenine/AHR signaling enhances disease aggressiveness in pancreatic cancer 9:30-9:45am

Miriam Durante – University of Siena

In vitro Assessment of NitDox Toxicity Towards Vasculature

9:45-10:00am

Asghar Ghasemi - Shahid Beheshti University of Medical Sciences

Effects of long-term nitrite supplementation on gene expressions of GLUT2, GLUT4 and glucokinase in male obese type 2 diabetic rats

10:00-10:15am

Zahra Bahadoran - Shahid Beheshti University of Medical Sciences

Serum Nitric Oxide Metabolites and The Incidence of Metabolic Syndrome and Its Phenotypes: A Population-Based Prospective Study

**10:15-10:45am** *Coffee break* 

#### Session 6

#### Nitric oxide and Non-Cardiovascular Diseases

Chairs: Lucia Morbidelli, Vincenzo Calderone

10:45-11:00am

Andreas Papapetropolous - National and Kapodistrian University of Athens

Hydrogen Sulfide as a Signaling Molecule in The Cardiovascular System: Actions and Interactions with NO. <a href="https://doi.org/10.11.10-11.15am">11.00-11.15am</a>

Josef Dulak - Jagiellonian University

Heme Oxygenase-1 In Duchenne Muscular Dystrophy: Interaction with Nitric Oxide Synthase Pathway in Satellite Cells Differentiation

11:15-11:30am

Stefan Chlopicki - Jagiellonian University

Pharmacology of Hepatoselective Nitric Oxide - Donors in NAFLD in Mice

11:30-11:45am

Giuseppe Filomeni - Danish Cancer Society Research Center

The Regulation of GSNOR Expression Discloses the Role of S-nitrosylation in Aging and Disease

12:00-12:30pm Coffee break & snacks

#### Session 7

#### **Nitric Oxide and Therapeutic Applications**

Chairs: Benjamin Bonavida, Salvatore Cuzzocrea

12:30-12:45pm

Chiara Platania – University of Catania

Therapeutic Potential of Nitric Oxide Modulation in Ocular Diseases: A Focus on Novel NO-Releasing Molecules

12:45-1:00pm

Rosana Pinto – University of Lisboa

**Emerging Nitric Oxide-releasing Porous Materials for Therapeutic Applications** 

1:00-1:15pm

Jan Scicinski - Avicenna Therapeutics, Inc

Cancer and Beyond: Discovery and Development of NO-releasing Therapeutics

1:15-1:45pm General discussion and concluding remarks (all chairs of sessions 1-7)